Cencora (COR)
Distributes pharmaceuticals and provides specialty-practice, logistics and manufacturer services worldwide.
Something off on this page? Send us feedback.
Cencora is the middleman that keeps medicines moving from drugmakers to pharmacies, hospitals, and clinics. Nearly all its sales still come from the American distribution machine, with two giant customers shaping the risk. It is becoming more involved in running specialist doctor networks while preparing to give up control of its animal-health arm.
Item facts: FY2025 · year ended Sep 30, 2025, from filings, earnings calls and company pages.
Judgment weights, not filed revenue
The band summarizes business focus and direction. ~ marks estimates.
6 in detail · 14 more below
U.S. Pharmaceutical Distribution Services
The enormous core moves medicines to American pharmacies and care providers. Walgreens/Boots accounts for 25% of company sales and Evernorth another 13%; lower expectations for high-priced weight-loss and diabetes drugs have slowed its sales outlook.
Competes with Pharmaceutical and Specialty Solutions (McKesson) · Pharmaceutical and Specialty Solutions (Cardinal Health)
In plain English
Picture a grocery wholesaler, but the shelves hold medicines and every delivery has stricter rules. Cencora buys brand-name drugs, cheaper copies, vaccines, and other health products, then sends them to pharmacies, hospitals, and doctors' offices.
Customers pay the full price of each order, yet Cencora keeps only a thin slice for buying well, storing safely, and delivering reliably. Huge volume makes that slice add up. Drugmakers need broad reach, while care providers keep returning because they cannot let essential stock run out.
Alliance Healthcare
Alliance is the European medicine wholesaler and brought in $24.39 billion in FY2025. Its steady demand meets a patchwork of national payment rules, controlled markups, and local delivery economics.
Competes with PHOENIX Pharmahandel (PHOENIX group) · GEHE Pharma Handel (McKesson) · NOWEDA (NOWEDA)
In plain English
Across Europe, a neighborhood pharmacy cannot order as though the continent were one country. Alliance buys medicines and replenishes pharmacies and hospitals through local warehouses and delivery routes, working under each country's rules.
The pharmacy or hospital pays for the medicine and Alliance keeps a small amount for getting it there. Frequent, tightly packed routes help that amount cover the cost of warehouses, drivers, and stock. People still need prescriptions in weak economies, but governments and manufacturers influence how much the wholesaler may keep.
World Courier and ICS
This pair stores and moves unusually sensitive treatments, including roughly 29,000 extremely cold shipments a year for therapies made from cells or genetic material. Every trip depends on temperature, correct patient matching, and smooth border handling.
Competes with Cell and Gene Therapy Logistics (Marken/UPS Healthcare) · Advanced Therapy Logistics (DHL Health Logistics)
In plain English
Some treatments are more like ice sculptures than parcels: one warm delay can ruin them. World Courier carries these fragile medicines and trial supplies between developers, hospitals, and patients, while ICS stores products, fills orders, collects payment, and keeps the handoffs connected.
Medicine makers pay for controlled boxes, a monitored journey, secure records, and dependable arrival. The service matters most when a shipment is scarce, made for one patient, or still being tested. More treatments made from cells or genetic material create demand, but a single broken handoff can destroy the cargo's value.
PharmaLex
PharmaLex helps medicine makers clear government and safety requirements. Cencora wrote off $1.14 billion of its value across FY2024 and FY2025; the question is whether the reorganized operation can deliver reliably.
Competes with Regulatory, safety, and market-access services (ProductLife Group) · Pharmacovigilance and medical-information services (ProPharma Group)
In plain English
Before and after a medicine reaches patients, someone must assemble approval papers, check safety reports, guard product quality, and explain why health systems should pay for it. PharmaLex supplies the specialists who do that work for drug developers.
Clients pay for people's time and know-how, much as a homeowner pays an architect to navigate building rules. Projects arrive when drugs are tested, launched, or monitored after launch. Cencora has rearranged the business after weaker demand and poor delivery, so keeping skilled staff busy and finishing work well now matter more than market growth promises.
Retina Consultants of America and OneOncology
These networks help independent eye and cancer doctors run their practices. OneOncology joined after FY2025; selected practices brought in $820 million over five months through June as Cencora moved closer to patient care.
Competes with The US Oncology Network (McKesson) · Navista (Cardinal Health)
In plain English
A small specialist clinic treats patients, but it also has to buy medicines, hire staff, manage bills, run research, and maintain computer systems. RCA supports retina doctors, who treat the back of the eye; OneOncology does similar work for cancer and urinary-system practices.
Cencora owns some practices and collects management fees from others. The doctors gain shared tools, buying power, and office support while keeping a degree of independence. Cencora earns more than the thin delivery slice and also deepens the medicine-ordering relationship, provided doctors stay and the networks integrate smoothly.
MWI Animal Health
MWI supplied $5.69 billion of medicines, vaccines, tests, and equipment to veterinary practices in FY2025. Cencora plans to combine it with Covetrus, but the deal remains under U.S. competition review.
Competes with North America distribution (Covetrus) · Veterinary distribution (Midwest Veterinary Supply)
In plain English
The patients have paws, hooves, or wings, but the job resembles Cencora's human-medicine business. MWI fills veterinary clinics with drugs, vaccines, test equipment, and everyday supplies from a broad set of animal-health makers.
Clinics pay for each order and return because they need dependable restocking for pet visits and livestock care. Cencora currently earns the distributor's slice on that flow. Its plan would trade control of MWI for cash, preferred securities that get paid before ordinary shares, and part ownership of a combined MWI and Covetrus, if competition officials allow it.
U.S. Pharmaceutical Distribution ServicesThe enormous core moves medicines to American pharmacies and care providers. Walgreens/Boots accounts for 25% of company sales and Evernorth another 13%; lower expectations for high-priced weight-loss and diabetes drugs have slowed its sales outlook.The enormous core moves medicines to American pharmacies and care providers. Walgreens/Boots accounts for 25% of company sales and Evernorth another 13%; lower expectations for high-priced weight-loss and diabetes drugs have slowed its sales outlook.
In plain English
Picture a grocery wholesaler, but the shelves hold medicines and every delivery has stricter rules. Cencora buys brand-name drugs, cheaper copies, vaccines, and other health products, then sends them to pharmacies, hospitals, and doctors' offices.
Customers pay the full price of each order, yet Cencora keeps only a thin slice for buying well, storing safely, and delivering reliably. Huge volume makes that slice add up. Drugmakers need broad reach, while care providers keep returning because they cannot let essential stock run out.
Competes with Pharmaceutical and Specialty Solutions (McKesson) · Pharmaceutical and Specialty Solutions (Cardinal Health)
Alliance HealthcareAlliance is the European medicine wholesaler and brought in $24.39 billion in FY2025. Its steady demand meets a patchwork of national payment rules, controlled markups, and local delivery economics.Alliance is the European medicine wholesaler and brought in $24.39 billion in FY2025. Its steady demand meets a patchwork of national payment rules, controlled markups, and local delivery economics.
In plain English
Across Europe, a neighborhood pharmacy cannot order as though the continent were one country. Alliance buys medicines and replenishes pharmacies and hospitals through local warehouses and delivery routes, working under each country's rules.
The pharmacy or hospital pays for the medicine and Alliance keeps a small amount for getting it there. Frequent, tightly packed routes help that amount cover the cost of warehouses, drivers, and stock. People still need prescriptions in weak economies, but governments and manufacturers influence how much the wholesaler may keep.
Competes with PHOENIX Pharmahandel (PHOENIX group) · GEHE Pharma Handel (McKesson) · NOWEDA (NOWEDA)
World Courier and ICSThis pair stores and moves unusually sensitive treatments, including roughly 29,000 extremely cold shipments a year for therapies made from cells or genetic material. Every trip depends on temperature, correct patient matching, and smooth border handling.This pair stores and moves unusually sensitive treatments, including roughly 29,000 extremely cold shipments a year for therapies made from cells or genetic material. Every trip depends on temperature, correct patient matching, and smooth border handling.
In plain English
Some treatments are more like ice sculptures than parcels: one warm delay can ruin them. World Courier carries these fragile medicines and trial supplies between developers, hospitals, and patients, while ICS stores products, fills orders, collects payment, and keeps the handoffs connected.
Medicine makers pay for controlled boxes, a monitored journey, secure records, and dependable arrival. The service matters most when a shipment is scarce, made for one patient, or still being tested. More treatments made from cells or genetic material create demand, but a single broken handoff can destroy the cargo's value.
Competes with Cell and Gene Therapy Logistics (Marken/UPS Healthcare) · Advanced Therapy Logistics (DHL Health Logistics)
PharmaLexPharmaLex helps medicine makers clear government and safety requirements. Cencora wrote off $1.14 billion of its value across FY2024 and FY2025; the question is whether the reorganized operation can deliver reliably.PharmaLex helps medicine makers clear government and safety requirements. Cencora wrote off $1.14 billion of its value across FY2024 and FY2025; the question is whether the reorganized operation can deliver reliably.
In plain English
Before and after a medicine reaches patients, someone must assemble approval papers, check safety reports, guard product quality, and explain why health systems should pay for it. PharmaLex supplies the specialists who do that work for drug developers.
Clients pay for people's time and know-how, much as a homeowner pays an architect to navigate building rules. Projects arrive when drugs are tested, launched, or monitored after launch. Cencora has rearranged the business after weaker demand and poor delivery, so keeping skilled staff busy and finishing work well now matter more than market growth promises.
Competes with Regulatory, safety, and market-access services (ProductLife Group) · Pharmacovigilance and medical-information services (ProPharma Group)
Retina Consultants of America and OneOncologyThese networks help independent eye and cancer doctors run their practices. OneOncology joined after FY2025; selected practices brought in $820 million over five months through June as Cencora moved closer to patient care.These networks help independent eye and cancer doctors run their practices. OneOncology joined after FY2025; selected practices brought in $820 million over five months through June as Cencora moved closer to patient care.
In plain English
A small specialist clinic treats patients, but it also has to buy medicines, hire staff, manage bills, run research, and maintain computer systems. RCA supports retina doctors, who treat the back of the eye; OneOncology does similar work for cancer and urinary-system practices.
Cencora owns some practices and collects management fees from others. The doctors gain shared tools, buying power, and office support while keeping a degree of independence. Cencora earns more than the thin delivery slice and also deepens the medicine-ordering relationship, provided doctors stay and the networks integrate smoothly.
Competes with The US Oncology Network (McKesson) · Navista (Cardinal Health)
MWI Animal HealthMWI supplied $5.69 billion of medicines, vaccines, tests, and equipment to veterinary practices in FY2025. Cencora plans to combine it with Covetrus, but the deal remains under U.S. competition review.MWI supplied $5.69 billion of medicines, vaccines, tests, and equipment to veterinary practices in FY2025. Cencora plans to combine it with Covetrus, but the deal remains under U.S. competition review.
In plain English
The patients have paws, hooves, or wings, but the job resembles Cencora's human-medicine business. MWI fills veterinary clinics with drugs, vaccines, test equipment, and everyday supplies from a broad set of animal-health makers.
Clinics pay for each order and return because they need dependable restocking for pet visits and livestock care. Cencora currently earns the distributor's slice on that flow. Its plan would trade control of MWI for cash, preferred securities that get paid before ordinary shares, and part ownership of a combined MWI and Covetrus, if competition officials allow it.
Competes with North America distribution (Covetrus) · Veterinary distribution (Midwest Veterinary Supply)
Named in filings, launches and programs
- ProfarmaBrandBrazilian healthcare distributor producing roughly $2 billion of FY2025 sales; Cencora is weighing what to do with it.
- Innomar StrategiesServiceCanadian service that helps drugmakers launch treatments, supports patients, runs pharmacies for complex medicines, and handles deliveries.
- AmerisourceBergen Drug CorporationBrandThe principal operating unit inside Cencora's full-line U.S. medicine-distribution business.
- ASD HealthcareBrandMedicine distributor serving health systems, specialist practices, and places that provide care outside hospitals.
- Besse MedicalBrandMedicine distributor focused on independent community doctor practices.
- Good Neighbor PharmacyEcosystemSupport and shared branding network for independent pharmacies that buy through Cencora's wholesale channel.
- Elevate Provider NetworkEcosystemAdministrative and pharmacy-services network that helps independent pharmacies operate within the U.S. distribution system.
- American Health PackagingBrandPackages medicines into ready-to-use individual doses for pharmacies and care institutions.
- BluePoint LaboratoriesBrandCencora's own-label program for lower-cost copies of brand-name medicines sold through its U.S. wholesale network.
- NucleusPlatform · RampingNew stock-tracking hardware and software being tried across roughly two dozen specialist-practice sites.
- Accelerate Pharmacy Solutions: Cell and Gene Therapy EnablementService · RampingHelps health systems prepare staff, payment, delivery, and patient steps for complex cell-and-gene treatments.
- Walgreens/Boots and WBAD arrangementsCustomer programLarge medicine-supply and joint buying relationships, with U.S. arrangements running through 2029 and Boots distribution through 2031.
- Evernorth Health Services relationshipCustomer programA major customer relationship whose contract length and exact mix of services are not separately disclosed.
- EyeSouth Partners' retina businessBrand · AnnouncedProposed $1.10 billion addition to RCA that had not closed and remained outside forecasts in August 2026.
ProfarmaBrand
Brazilian healthcare distributor producing roughly $2 billion of FY2025 sales; Cencora is weighing what to do with it.
Innomar StrategiesService
Canadian service that helps drugmakers launch treatments, supports patients, runs pharmacies for complex medicines, and handles deliveries.
AmerisourceBergen Drug CorporationBrand
The principal operating unit inside Cencora's full-line U.S. medicine-distribution business.
ASD HealthcareBrand
Medicine distributor serving health systems, specialist practices, and places that provide care outside hospitals.
Besse MedicalBrand
Medicine distributor focused on independent community doctor practices.
Good Neighbor PharmacyEcosystem
Support and shared branding network for independent pharmacies that buy through Cencora's wholesale channel.
Elevate Provider NetworkEcosystem
Administrative and pharmacy-services network that helps independent pharmacies operate within the U.S. distribution system.
American Health PackagingBrand
Packages medicines into ready-to-use individual doses for pharmacies and care institutions.
BluePoint LaboratoriesBrand
Cencora's own-label program for lower-cost copies of brand-name medicines sold through its U.S. wholesale network.
NucleusPlatform · Ramping
New stock-tracking hardware and software being tried across roughly two dozen specialist-practice sites.
Accelerate Pharmacy Solutions: Cell and Gene Therapy EnablementService · Ramping
Helps health systems prepare staff, payment, delivery, and patient steps for complex cell-and-gene treatments.
Walgreens/Boots and WBAD arrangementsCustomer program
Large medicine-supply and joint buying relationships, with U.S. arrangements running through 2029 and Boots distribution through 2031.
Evernorth Health Services relationshipCustomer program
A major customer relationship whose contract length and exact mix of services are not separately disclosed.
EyeSouth Partners' retina businessBrand · Announced
Proposed $1.10 billion addition to RCA that had not closed and remained outside forecasts in August 2026.